Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape

PLoS Pathogens

Volumn 13, Issue 1, 2017, Pages

  Wibmer, Constantinos Kurt ^a,b   Gorman, Jason ^c   Ozorowski, Gabriel ^d   Bhiman, Jinal N ^a,b   Sheward, Daniel J ^e   Elliott, Debra H ^f   Rouelle, Julie ^f   Smira, Ashley ^f   Joyce, M Gordon ^c   Ndabambi, Nonkululeko ^e   Druz, Aliaksandr ^c   Asokan, Mangai ^c   Burton, Dennis R ^d,g   Connors, Mark ^c   Abdool Karim, Salim S ^h,i   Mascola, John R ^c   Robinson, James E ^f   Ward, Andrew B ^d   Williamson, Carolyn ^e,h   Kwong, Peter D ^c   Morris, Lynn ^a,b,h   Moore, Penny L ^a,b,h   more..

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h UNIVERSITY OF KWAZULU NATAL   (South Africa)

ⁱ Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CAP248 2B; UNCLASSIFIED DRUG; COMPLEMENTARITY DETERMINING REGION; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SOLUBLE CD4 ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ANTIGEN RECOGNITION; ARTICLE; B CELL CULTURE; BINDING ASSAY; CELL SURFACE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMAGE RECONSTRUCTION; IMMUNOGLOBULIN GENE; MOLECULAR CLONING; MOLECULAR DOCKING; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN SYNTHESIS; SITE DIRECTED MUTAGENESIS; VIRAL ESCAPE; VIRAL PHENOMENA AND FUNCTIONS; VIRUS INHIBITION; VIRUS NEUTRALIZATION; X RAY CRYSTALLOGRAPHY; GENETICS; GLYCOSYLATION; HELA CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGY; ISOLATION AND PURIFICATION; SERODIAGNOSIS; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; COMPLEMENTARITY DETERMINING REGIONS; CRYSTALLOGRAPHY, X-RAY; EPITOPES; GLYCOSYLATION; HELA CELLS; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS;

EID: 85010952279     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006074     Document Type: Article

References (88)

1. Mascola JR, Montefiori DC, The role of antibodies in HIV vaccines. Annu Rev Immunol. 2010;28:413–44. Epub 2010/03/03. doi: 10.1146/annurev-immunol-030409-10125620192810
2. Earl PL, Doms RW, Moss B, Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proceedings of the National Academy of Sciences of the United States of America. 1990;87(2):648–52. 2300552
3. Earl PL, Moss B, Doms RW, Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. Journal of virology. 1991;65(4):2047–55. 1900540
4. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR, et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell. 1988;53(1):55–67. 2450679
5. Freed EO, Myers DJ, Risser R, Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. Journal of virology. 1989;63(11):4670–5. 2677400
6. Kieny MP, Lathe R, Riviere Y, Dott K, Schmitt D, Girard M, et al. Improved antigenicity of the HIV env protein by cleavage site removal. Protein Eng. 1988;2(3):219–25. 3237686
7. Moore JP, McKeating JA, Weiss RA, Sattentau QJ, Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 1990;250(4984):1139–42. 2251501
8. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. Journal of virology. 2008;82(24):12449–63. doi: 10.1128/JVI.01708-0818842730
9. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. Journal of virology. 2007;81(12):6187–96. doi: 10.1128/JVI.00239-0717409164
10. Richman DD, Wrin T, Little SJ, Petropoulos CJ, Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(7):4144–9. doi: 10.1073/pnas.063053010012644702
11. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. Journal of virology. 2006;80(11):5211–8. Epub 2006/05/16. doi: 10.1128/JVI.00201-0616699001
12. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422(6929):307–12. 12646921
13. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM, Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. Journal of virology. 1997;71(5):3734–41. 9094648
14. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT, Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. Aids. 2014;28(2):163–9. 24361678
15. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. Journal of virology. 2011;85(10):4828–40. Epub 2011/03/11. doi: 10.1128/JVI.00198-1121389135
16. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. Journal of virology. 2009;83(1):188–99. doi: 10.1128/JVI.01583-0818922865
17. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. Journal of virology. 2009;83(2):757–69. doi: 10.1128/JVI.02036-0818987148
18. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(46):18921–5. doi: 10.1073/pnas.121478510923100539
19. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Science translational medicine. 2014;6(243):243ra88. doi: 10.1126/scitranslmed.300899224990883
20. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature medicine. 2000;6(2):200–6. doi: 10.1038/7230910655110
21. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature medicine. 2009;15(8):951–4. Epub 2009/06/16. doi: 10.1038/nm.197419525965
22. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature medicine. 2000;6(2):207–10. doi: 10.1038/7231810655111
23. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. Journal of virology. 2001;75(17):8340–7. doi: 10.1128/JVI.75.17.8340-8347.200111483779
24. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nature medicine. 2003;9(3):343–6. doi: 10.1038/nm83312579198
25. Kwong PD, Mascola JR, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012;37(3):412–25. doi: 10.1016/j.immuni.2012.08.01222999947
26. Verkoczy L, Kelsoe G, Moody MA, Haynes BF, Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol. 2011;23(3):383–90. doi: 10.1016/j.coi.2011.04.00321524897
27. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153(1):126–38. doi: 10.1016/j.cell.2013.03.01823540694
28. Doores KJ, Burton DR, Variable loop glycan dependency of the broad and potent HIV-1 neutralizing antibodies PG9 and PG16. Journal of virology. 2010. Epub 2010/08/06.
29. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, et al. Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity. 2014.
30. Kim AS, Leaman DP, Zwick MB, Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS pathogens. 2014;10(7):e1004271. doi: 10.1371/journal.ppat.100427125058619
31. Pritchard LK, Spencer DI, Royle L, Vasiljevic S, Krumm SA, Doores KJ, et al. Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. Journal of virology. 2015;89(13):6952–9. doi: 10.1128/JVI.00230-1525878100
32. Doores KJ, The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J. 2015.
33. McCoy LE, Falkowska E, Doores KJ, Le K, Sok D, van Gils MJ, et al. Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS pathogens. 2015;11(8):e1005110. doi: 10.1371/journal.ppat.100511026267277
34. Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2014;505(7484):502–8. doi: 10.1038/nature1289324352234
35. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498):55–62. doi: 10.1038/nature1303624590074
36. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496(7446):469–76. doi: 10.1038/nature1205323552890
37. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466–70. Epub 2011/08/19. doi: 10.1038/nature1037321849977
38. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–9. doi: 10.1126/science.117874619729618
39. Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(49):17624–9. doi: 10.1073/pnas.141578911125422458
40. Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. Journal of virology. 2012;86(8):4688–92. doi: 10.1128/JVI.07163-1122301150
41. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61. Epub 2010/07/10. doi: 10.1126/science.118765920616233
42. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PloS one. 2010;5(1):e8805. Epub 2010/01/26. doi: 10.1371/journal.pone.000880520098712
43. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2009;343(2):65–7. doi: 10.1016/j.jim.2008.11.01219100741
44. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014;515(7525):138–42. doi: 10.1038/nature1360125186731
45. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406–12. doi: 10.1038/nature1154423151583
46. Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. The Journal of experimental medicine. 2012;209(8):1469–79. doi: 10.1084/jem.2012042322826297
47. Scharf L, Scheid JF, Lee JH, West AP, Jr.Chen C, Gao H, et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell reports. 2014;7(3):785–95. doi: 10.1016/j.celrep.2014.04.00124767986
48. Lee JH, Leaman DP, Kim AS, Torrents de la Pena A, Sliepen K, Yasmeen A, et al. Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nat Commun. 2015;6:8167. doi: 10.1038/ncomms916726404402
49. Wibmer CK, Moore PL, Morris L, HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS. 2015;10(3):135–43. 25760932
50. Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K, et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science. 2016;352(6287):828–33. doi: 10.1126/science.aae047427174988
51. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C, et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS pathogens. 2013;9(10):e1003738. doi: 10.1371/journal.ppat.100373824204277
52. Mikell I, Stamatatos L, Evolution of Cross-Neutralizing Antibody Specificities to the CD4-BS and the Carbohydrate Cloak of the HIV Env in an HIV-1-Infected Subject. PloS one. 2012;7(11):e49610. doi: 10.1371/journal.pone.004961023152926
53. Wang W, Nie J, Prochnow C, Truong C, Jia Z, Wang S, et al. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology. 2013;10:14. doi: 10.1186/1742-4690-10-1423384254
54. Yang X, Florin L, Farzan M, Kolchinsky P, Kwong PD, Sodroski J, et al. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. Journal of virology. 2000;74(10):4746–54. 10775613
55. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308(5730):1906–8. doi: 10.1126/science.111178115860590
56. Behrens AJ, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, et al. Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell reports. 2016;14(11):2695–706. doi: 10.1016/j.celrep.2016.02.05826972002
57. West AP, Jr.Scharf L, Horwitz J, Klein F, Nussenzweig MC, Bjorkman PJ, Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proceedings of the National Academy of Sciences of the United States of America. 2013.
58. Guttman M, Kahn M, Garcia NK, Hu SL, Lee KK, Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120. Journal of virology. 2012;86(16):8750–64. doi: 10.1128/JVI.07224-1122674993
59. Go EP, Hewawasam G, Liao HX, Chen H, Ping LH, Anderson JA, et al. Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. Journal of virology. 2011;85(16):8270–84. Epub 2011/06/10. doi: 10.1128/JVI.05053-1121653661
60. Stansell E, Panico M, Canis K, Pang PC, Bouche L, Binet D, et al. Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate. PloS one. 2015;10(4):e0124784. doi: 10.1371/journal.pone.012478425915761
61. Go EP, Herschhorn A, Gu C, Castillo-Menendez L, Zhang S, Mao Y, et al. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140. Journal of virology. 2015;89(16):8245–57. doi: 10.1128/JVI.00628-1526018173
62. Yang W, Shah P, Toghi Eshghi S, Yang S, Sun S, Ao M, et al. Glycoform analysis of recombinant and human immunodeficiency virus envelope protein gp120 via higher energy collisional dissociation and spectral-aligning strategy. Anal Chem. 2014;86(14):6959–67. doi: 10.1021/ac500876p24941220
63. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, de la Pena AT, et al. Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers. Immunity. 2014.
64. Scharf L, Wang H, Gao H, Chen S, McDowall AW, Bjorkman PJ, Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. Cell. 2015;162(6):1379–90. doi: 10.1016/j.cell.2015.08.03526359989
65. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014;514(7523):455–61. doi: 10.1038/nature1380825296255
66. Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather DN, Marcovecchio PM, et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. The Journal of experimental medicine. 2013;210(6):1235–49. doi: 10.1084/jem.2013022123712429
67. Stewart-Jones GB, Soto C, Lemmin T, Chuang GY, Druz A, Kong R, et al. Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell. 2016;165(4):813–26. doi: 10.1016/j.cell.2016.04.01027114034
68. Chen J, Frey G, Peng H, Rits-Volloch S, Garrity J, Seaman MS, et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. Journal of virology. 2014;88(2):1249–58. doi: 10.1128/JVI.02664-1324227838
69. Rathinakumar R, Dutta M, Zhu P, Johnson WE, Roux KH, Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions. Journal of virology. 2012;86(3):1820–31. doi: 10.1128/JVI.05489-1122090143
70. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B, A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(10):3739–44. doi: 10.1073/pnas.080025510518322015
71. Chakrabarti BK, Walker LM, Guenaga JF, Ghobbeh A, Poignard P, Burton DR, et al. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. Journal of virology. 2011;85(16):8217–26. doi: 10.1128/JVI.00756-1121653673
72. Irimia A, Sarkar A, Stanfield RL, Wilson IA, Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10. Immunity. 2016;44(1):21–31. doi: 10.1016/j.immuni.2015.12.00126777395
73. McCoy LE, van Gils MJ, Ozorowski G, Messmer T, Briney B, Voss JE, et al. Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell reports. 2016.
74. Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, Montefiori DC, et al. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. Journal of virology. 2010;84(7):3443–53. doi: 10.1128/JVI.02617-0920106929
75. Liao HX, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods. 2009;158(1–2):171–9. doi: 10.1016/j.jviromet.2009.02.01419428587
76. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc. 2009;4(3):372–84. doi: 10.1038/nprot.2009.319247287
77. Benoit RM, Wilhelm RN, Scherer-Becker D, Ostermeier C, An improved method for fast, robust, and seamless integration of DNA fragments into multiple plasmids. Protein Expr Purif. 2006;45(1):66–71. doi: 10.1016/j.pep.2005.09.02216289702
78. Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, Zhang Z, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(10):3952–7. doi: 10.1073/pnas.081339210619225108
79. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. Journal of virology. 2008;82(8):3952–70. doi: 10.1128/JVI.02660-0718256145
80. Montefiori DC, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R, Evaluating neutralizing antibodies againts HIV, SIV and SHIV in luciferase reporter gene assays. In: Current Protocols in Immunology: John Wiley & Sons; 2004.
81. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12. doi: 10.1002/jcc.2008415264254
82. Suloway C, Pulokas J, Fellmann D, Cheng A, Guerra F, Quispe J, et al. Automated molecular microscopy: the new Leginon system. J Struct Biol. 2005;151(1):41–60. doi: 10.1016/j.jsb.2005.03.01015890530
83. Lander GC, Stagg SM, Voss NR, Cheng A, Fellmann D, Pulokas J, et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J Struct Biol. 2009;166(1):95–102. doi: 10.1016/j.jsb.2009.01.00219263523
84. Tang G, Peng L, Baldwin PR, Mann DS, Jiang W, Rees I, et al. EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol. 2007;157(1):38–46. doi: 10.1016/j.jsb.2006.05.00916859925
85. Penczek PA, Grassucci RA, Frank J, The ribosome at improved resolution: new techniques for merging and orientation refinement in 3D cryo-electron microscopy of biological particles. Ultramicroscopy. 1994;53(3):251–70. 8160308
86. Pancera M, Wyatt R, Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology. 2005;332(1):145–56. doi: 10.1016/j.virol.2004.10.04215661147
87. Andrabi R, Voss JE, Liang CH, Briney B, McCoy LE, Wu CY, et al. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. Immunity. 2015;43(5):959–73. doi: 10.1016/j.immuni.2015.10.01426588781
88. Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT, the international ImMunoGeneTics information system. Nucleic acids research. 2009;37(Database issue):D1006–12. doi: 10.1093/nar/gkn83818978023